CRESTOR Demonstrates CV Risk Reduction in a Large Statin Outcomes Study
New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
Results also showed that for patients in the trial taking rosuvastatin:
- the combined risk of heart attack, stroke or CV death was reduced by nearly half (47%, p<0.001).
- risk of heart attack was cut by more than half (54%, p<0.001).
- risk of stroke was cut by nearly half (48%, p=0.002).
- total mortality was significantly reduced by 20% (p=0.02).
These results were accompanied by a median LDL-C reduction of 50% (p<0.001) resulting in an on-treatment median LDL-C of 55 mg/dL.
On the basis of the data, if the results are projected over a period of 5 years, 25 patients would need to be treated to prevent one major cardiovascular event (NNT=25).
The JUPITER results were published online by the New England Journal of Medicine.
Other news from the department research and development
